FMP

FMP

Enter

ALIM - Alimera Sciences, In...

photo-url-https://images.financialmodelingprep.com/symbol/ALIM.png

Alimera Sciences, Inc.

ALIM

NASDAQ

Inactive Equity

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

5.54 USD

-0.01 (-0.181%)

Latest ALIM News

Zacks Investment Research

Aug 6, 2024

Alimera Sciences (ALIM) Reports Q2 Loss, Tops Revenue Estimates

Alimera Sciences (ALIM) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.44 per share a year ago.

Read More

Zacks Investment Research

Jun 25, 2024

Alimera (ALIM) Rises on Merger Deal With ANI Pharmaceuticals

Alimera (ALIM) is set to be acquired by ANI Pharmaceuticals for approximately $381 million in upfront consideration. The transaction is expected to close in the third quarter of 2024.

Read More

Benzinga

Jun 24, 2024

Dow Jumps 300 Points; Alimera Sciences Shares Spike Higher

U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining more than 300 points on Monday.

Read More

InvestorPlace

Jun 24, 2024

Why Is Alimera Sciences (ALIM) Stock Up 77% Today?

Alimera Sciences (NASDAQ: ALIM ) stock is rocketing higher on Monday after the pharmaceutical company announced an acquisition deal with ANI Pharmaceuticals (NASDAQ: ANIP ). This agreement will have ANI Pharmaceuticals paying $5.50 per share for ALIM stock.

Read More

Invezz

Jun 24, 2024

Alimera Sciences stock rallies 75% on ANI Pharmaceuticals deal

Alimera Sciences Inc (NASDAQ: ALIM) rallied a whopping 75% in premarket today after ANI Pharmaceuticals Inc (NASDAQ: ANIP) said it will buy the Alpharetta, Georgia based company for about $381 million.  ANI shares are roughly flat at writing.

Read More

Zacks Investment Research

May 14, 2024

Alimera Sciences (ALIM) Reports Q1 Loss, Misses Revenue Estimates

Alimera Sciences (ALIM) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.71 per share a year ago.

Read More

Zacks Investment Research

Mar 13, 2024

New Strong Sell Stocks for March 13th

ASLE, ALIM and CADE have been added to the Zacks Rank #5 (Strong Sell) List on March 13, 2024.

Read More

Zacks Investment Research

Mar 7, 2024

Alimera Sciences (ALIM) Reports Q4 Loss, Tops Revenue Estimates

Alimera Sciences (ALIM) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of $0.02. This compares to loss of $0.54 per share a year ago.

Read More

Zacks Investment Research

Aug 10, 2023

Alimera Sciences (ALIM) Reports Q2 Loss, Lags Revenue Estimates

Alimera Sciences (ALIM) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of $0.06. This compares to loss of $0.45 per share a year ago.

Read More

GlobeNewsWire

Aug 2, 2023

Alimera Sciences to Report Second Quarter 2023 Financial Results on August 10, 2023, and Provide Corporate Update

ATLANTA, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will report second quarter financial results on August 10, 2023, prior to the market open. Management will host a conference call at 9:00 AM ET on the same day, to review financial results and provide an update on...

Read More
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep